O
MRTX

OrbiMed’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

OrbiMed’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,959,050
Closed -$85.3M – 138
2023
Q3 		$85.3M Buy
1,959,050
+1,045,400
+114% +$37.3M 1.81% 15
2023
Q2 		$33M Hold
913,650
– – 0.6% 54
2023
Q1 		$34M Sell
913,650
-370,042
-29% -$16.6M 0.67% 48
2022
Q4 		$58.2M Sell
1,283,692
-135,200
-10% -$8.75M 1.11% 34
2022
Q3 		$99.1K Buy
1,418,892
+328,492
+30% +$24.3M 1.84% 18
2022
Q2 		$73.2K Sell
1,090,400
-540,100
-33% -$34.3M 1.33% 27
2022
Q1 		$134M Buy
1,630,500
+204,100
+14% +$20.9M 2.17% 14
2021
Q4 		$209M Buy
1,426,400
+53,200
+4% +$8.26M 2.69% 7
2021
Q3 		$243M Buy
1,373,200
+109,000
+9% +$17.5M 2.67% 8
2021
Q2 		$204M Buy
1,264,200
+43,000
+4% +$6.9M 2.07% 13
2021
Q1 		$209M Buy
1,221,200
+75,900
+7% +$15M 1.96% 16
2020
Q4 		$252M Sell
1,145,300
-171,700
-13% -$37.1M 2.2% 9
2020
Q3 		$219M Sell
1,317,000
-7,100
-0.5% -$972K 2.75% 8
2020
Q2 		$151M Sell
1,324,100
-99,200
-7% -$9.62M 2.13% 16
2020
Q1 		$109M Buy
1,423,300
+82,700
+6% +$7.42M 1.84% 17
2019
Q4 		$173M Buy
1,340,600
+805,457
+151% +$77.7M 2.47% 10
2019
Q3 		$41.7M Buy
+535,143
New +$50.2M 0.79% 41
2016
Q2 		– Sell
-197,859
Closed -$4.23M – 145
2016
Q1 		$4.23M Buy
197,859
+165,659
+514% +$3.7M 0.04% 120
2015
Q4 		$1.02M Sell
32,200
-207,800
-87% -$7.34M 0.01% 124
2015
Q3 		$8.26M Sell
240,000
-440,500
-65% -$13.3M 0.08% 98
2015
Q2 		$21.4M Sell
680,500
-586,500
-46% -$17.3M 0.18% 82
2015
Q1 		$37.1M Buy
1,267,000
+100,000
+9% +$2.35M 0.32% 62
2014
Q4 		$21.6M Hold
1,167,000
– – 0.21% 72
2014
Q3 		$20.4M Sell
1,167,000
-5,000
-0.4% -$93.3K 0.21% 76
2014
Q2 		$23.4M Sell
1,172,000
-102,332
-8% -$1.98M 0.28% 60
2014
Q1 		$24.3M Hold
1,274,332
– – 0.3% 59
2013
Q4 		$21.2M Buy
1,274,332
+125,000
+11% +$2.14M 0.31% 62
2013
Q3 		$17.4M Buy
+1,149,332
New +$11.3M 0.31% 59

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

OrbiMed's MRTX Position: Q4 2023 in Review

OrbiMed sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 1,959,050 shares — an estimated $85.3M sold.

OrbiMed first reported a position in MRTX in Q3 2013 and held it in 28 quarters. The position peaked at $252M in Q4 2020. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • OrbiMed reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • OrbiMed sold 1,959,050 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $85.3M.
  • OrbiMed first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 28 quarters.
  • OrbiMed's Mirati Therapeutics, Inc. Common Stock position peaked at $252M in Q4 2020.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.